Spaulding Clinical Research to Perform Bioequivalence Study for One of World's Largest Pharmaceutical Companies

9/13/2010 1:16:06 PM

WEST BEND, Wis.--(BUSINESS WIRE)--Spaulding Clinical, a Phase 1 Clinical Pharmacology Research Unit and Core ECG Lab announced today that it will serve as the Phase 1 clinical site for an upcoming bioequivalence study for one of the world’s top five pharmaceutical companies.

Read at BioSpace.com

Read Article at

Related Companies

News Categories

• BioSpace.com

• Spaulding Clinical Research

• Clinical - Phase I